Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership
Signs Agreement With China’s Bio-Thera Solutions Worth Over $30m
Executive Summary
Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.
You may also be interested in...
Dr Reddy’s Is Latest Rumored Buyer For Biogen’s Biosimilars
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
Samsung Bioepis Responds To Rumor Of Biogen Biosimilars Buyout
Rumors of another major biosimilars deal are spreading after Korean media reported that Samsung Bioepis could be considering a bid for Biogen’s biosimilars business.
Bio-Thera Moves Ahead With Secukinumab And Mepolizumab
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).